

2024 ANNUAL REPORT



Lilly Cares® Foundation

In 2024, the Lilly Cares
Foundation had the
continued privilege
of making a significant
impact on patients' lives,
especially as many
low-income Americans
faced increased
economic hardships.



We were proud to provide nearly 165,000 eligible patients free donated Eli Lilly and Company (Lilly) medications, ensuring they received the treatments they needed without financial burden.

This year, Lilly Cares Foundation was able to add Lilly medications to treat Alzheimer's Disease (Kisunla™) and atopic dermatitis (Ebglyss®), expanding support to more patients with critical health needs.

The free medicines provided to patients this year through the Lilly Cares Foundation are valued at more than \$3.7 billion, reflecting our strong commitment to patient care. We are excited to continue being a reliable source of support, ensuring financial stress does not stand in the way of patients receiving the medicines they need.

Behind every patient we serve, there is a story of strength and resilience. It is these stories that drive us to do our best work and remind us of the importance of our mission.

I hope you find this annual report helpful and informative. Please visit **www.lillycares.com** for more information about Lilly Cares Foundation.


Irma Tragesser

President, Lilly Cares Foundation


Ima t. Tragesser







Nearly 18% of enrolled patients were able to receive multiple medications from Lilly Cares at no cost. More than **5,500 patients** in need received at least 3 prescribed medications.



\$3.7+ Billion
in Medications Provided

Nearly **700,000 shipments of medication** were delivered to patients' homes or their doctor's offices throughout the U.S.

Migraine, Alzheimer's)





Diabetes

- BAQSIMI® (glucagon) nasal powder
- Basaglar® (insulin glargine injection)
- Humalog® (insulin lispro injection)
- Humulin® (human insulin)
- Lyumjev® (insulin lispro-aabc) injection
- Trulicity® (dulaglutide) injection



Cancer

- Alimta® (pemetrexed for injection)
- Cyramza® (ramucirumab) injection
- Erbitux® (cetuximab) injection
- Jaypirca® (pirtobrutinib)
- Retevmo® (selpercatinib)
- Verzenio® (abemaciclih)



Immune Disorders

- Ebglyss® (lebrikizumab-lbkz) injection
- Olumiant® (baricitinib)
- Omvoh® (mirikizumab-mrkz) injection
- Taltz® (ixekizumab) injection



Neuroscience

(Mental Health, Migraine, Alzheimer's)


- Cymbalta® (duloxetine delayed-release capsules)
- Emgality® (galcanezumab-gnlm) injection
- Kisunla[™] (donanemab-azbt) injection
- Prozac® (fluoxetine)
- REYVOW® (lasmiditan)
- Strattera® (atomoxetine)
- Zyprexa® (olanzapine)



Women's, Men's, and Children's Health

- Cialis® (tadalafil)
- Evista® (raloxifene hydrochloride)
- Forteo® (teriparatide injection)
- Humatrope® (somatropin) for injection





Please visit www.lillycares.com

for more information about the Lilly Cares Foundation Patient Assistance Program.



Lilly Cares® Foundation, Inc., Lilly Corporate Center, Indianapolis, IN 46285.

Lilly Cares® is a registered trademark of Eli Lilly and Company. All medications listed in this report are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. BAQSIMI® and Zyprexa® are registered trademarks of their respective owners.

PP-AP-US-0680 04/2025 © Lilly Cares® Foundation 2025. All rights reserved.